Biotech company Targacept Inc (TRGT.O) said British drugmaker AstraZeneca (AZN.L) would return rights to several pre-clinical compounds, sending the U.S. company’s shares down 10 percent in extended trading. A licensing agreement, signed in 2005, continues for the remaining compounds, including AZD1446, a potential treatment for Alzheimer’s disease.
Help employers find you! Check out all the jobs and post your resume.
